Newsfeeds - Spark Newswire

1 minute read

Amicus Therapeutics Q2 EPS $(0.19) Beats $(0.22) Estimate, Galafold Revenue $77.4M, Up 24% YoY

August 5, 7:43 AM

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 5 percent increase over losses of $(0.20) per share from

FOLD

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

August 5, 4:08 AM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

1 minute read

Amicus’s Fabry Disease Medicine Gets European Approval For Use In Adolescents

By Vandana Singh

August 2, 8:50 AM

The European Commission has approved Amicus Therapeutics Inc (NASDAQ:FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an…

FOLD

9 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

July 23, 11:00 AM

Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.

ABCL

6 minute read

14 Biotech Stocks To Watch Over The Next 6 Months

By Shanthi Rexaline

June 23, 12:44 PM

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.

AERI

2 minute read

News

Amicus Therapeutics Insights: Return On Capital Employed

By Benzinga Insights

June 23, 10:48 AM

Amicus Therapeutics (NASDAQ:FOLD) reported Q1 sales of $66.40 million. Earnings fell to a loss of $52.58 million, resulting in a 18.31% decrease from last quarter. In Q4, Amicus Therapeutics brought in $70.57 million in sales but lost $64.37 million in earnings.

FOLD

1 minute read

Legal
News

Amicus Therapeutics Granted U.S. Patent Titled ‘Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones’

By Benzinga Newsdesk

June 15, 1:55 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6710&f=G&l=50&d=PTXT&p=135&S1=20210615&OS=20210615&RS=20210615

FOLD

5 minute read

Uncategorized

The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal

By Shanthi Rexaline

May 25, 7:53 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24)

ADVM

13 minute read

Uncategorized

Earnings Scheduled For May 10, 2021

By Benzinga Insights

May 10, 4:09 AM

Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.

ACEL

6 minute read

Uncategorized

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

By Shanthi Rexaline

May 9, 10:20 AM

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.

ABCL